101
|
Mizukami K, Sato M, Homma T, Natsui H, Kato M, Otsu K, Myojo T, Muto H, Fujita M, Takenaka T. P861Positioning an ECG electrode to the dorsal side can record higher amplitude of diaphragmatic compound motor action potentials (CMAP) during cryoballoon ablation. Europace 2017. [DOI: 10.1093/ehjci/eux151.043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
102
|
Sato M, Ochiai Y, Kijima S, Nagai N, Ando Y, Shikano M, Nomura Y. Quantitative Modeling and Simulation in PMDA: A Japanese Regulatory Perspective. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY 2017; 6:413-415. [PMID: 28568566 PMCID: PMC5529733 DOI: 10.1002/psp4.12203] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/20/2017] [Revised: 04/20/2017] [Accepted: 04/21/2017] [Indexed: 12/25/2022]
Abstract
In Japan in October 2016, the Pharmaceuticals and Medical Devices Agency (PMDA) began to receive electronic data in new drug applications (NDAs). These electronic data are useful to conduct regulatory assessment of sponsors’ submissions and contribute to the PMDA's research. In this article, we summarize the number of submissions of quantitative modeling and simulation (M&S) documents in NDAs in Japan, and we describe our current thinking and activities about quantitative M&S in PMDA.
Collapse
|
103
|
Komori A, Morisaki T, Mutoh T, Sakakibara S, Takeiri Y, Kumazawa R, Kubo S, Ida K, Morita S, Narihara K, Shimozuma T, Tanaka K, Watanabe KY, Yamada H, Yoshinuma M, Akiyama T, Ashikawa N, Emoto M, Funaba H, Goto M, Ido T, Ikeda K, Inagaki S, Isobe M, Igami H, Itoh K, Kaneko O, Kawahata K, Kobuchi T, Masuzaki S, Matsuoka K, Minami T, Miyazawa J, Muto S, Nagayama Y, Nakamura Y, Nakanishi H, Narushima Y, Nishimura K, Nishiura M, Nishizawa A, Noda N, Ohdachi S, Oka Y, Osakabe M, Ohyabu N, Ozaki T, Peterson BJ, Sagara A, Saito K, Sakamoto R, Sato K, Sato M, Seki T, Shoji M, Sudo S, Tamura N, Toi K, Tokuzawa T, Tsumori K, Uda T, Watari T, Yamada I, Yokoyama M, Yoshimura Y, Motojima O, Beidler CD, Fujita T, Isayama A, Sakamoto Y, Takenaga H, Goncharov P, Ishii K, Sakamoto M, Murakami S, Notake T, Takeuchi N, Okajima S, Sasao M. Overview of Progress in LHD Experiments. FUSION SCIENCE AND TECHNOLOGY 2017. [DOI: 10.13182/fst06-a1229] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
104
|
Sugie T, Hatae T, Koide Y, Fujita T, Kusama Y, Nishitani T, Isayama A, Sato M, Shinohara K, Asakura N, Konoshima S, Kubo H, Takenaga H, Kawano Y, Kondoh T, Nagashima A, Fukuda T, Sunaoshi H, Naito O, Kitamura S, Tsukahara Y, Sakasai A, Sakamoto Y, Suzuki T, Tobita K, Nemoto M, Morioka A, Ishikawa M, Ishida S, Isei N, Oyama N, Neyatani Y, Itami K, Sakurai S, Tamai H, Tsuchiya K, Higashijima S, Nakano T, Nagaya S, Chiba S, Lee S, Shitomi M. Diagnostics System of JT-60U. FUSION SCIENCE AND TECHNOLOGY 2017. [DOI: 10.13182/fst02-a242] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
105
|
Kasai S, Kamiya K, Shinohara K, Kawashima H, Ogawa H, Uehara K, Miura Y, Okano F, Suzuki S, Hoshino K, Tsuzuki K, Sato M, Oasa K, Kusama Y, Yamauchi T, Nagashima Y, Ida K, Hidekuma S, Ido T, Hamada Y, Nishizawa A, Kawasumi Y, Uesugi Y, Okajima S, Kawahata K, Ejiri A, Amemiya H, Sadamoto Y. Plasma Diagnostics in JFT-2M. FUSION SCIENCE AND TECHNOLOGY 2017. [DOI: 10.13182/fst06-a1097] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
106
|
Takeiri Y, Kaneko O, Tsumori K, Osakabe M, Ikeda K, Nagaoka K, Nakano H, Asano E, Kondo T, Sato M, Shibuya M, Komada S. High Performance of Neutral Beam Injectors for Extension of LHD Operational Regime. FUSION SCIENCE AND TECHNOLOGY 2017. [DOI: 10.13182/fst10-a10834] [Citation(s) in RCA: 54] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
107
|
Kamada Y, Fujita T, Ishida S, Kikuchi M, Ide S, Takizuka T, Shirai H, Koide Y, Fukuda T, Hosogane N, Tsuchiya K, Hatae T, Takenaga H, Sato M, Nakamura H, Naito O, Asakura N, Kubo H, Higashijima S, Miura Y, Yoshino R, Shimizu K, Ozeki T, Hirayama T, Mori M, Sakamoto Y, Kawano Y, Isayama A, Ushigusa K, Ikeda Y, Kimura H, Fujii T, Imai T, Nagami M, Takeji S, Oikawa T, Suzuki T, Nakano T, Oyama N, Sakurai S, Konoshima S, Sugie T, Tobita K, Kondoh T, Tamai H, Neyatani Y, Sakasai A, Kusama Y, Itami K, Shimada M, Ninomiya H, Urano H. Fusion Plasma Performance and Confinement Studies on JT-60 and JT-60U. FUSION SCIENCE AND TECHNOLOGY 2017. [DOI: 10.13182/fst02-a227] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
108
|
Tsumori K, Takeiri Y, Kaneko O, Osakabe M, Ando A, Ikeda K, Nagaoka K, Nakano H, Asano E, Shibuya M, Sato M, Kondo T, Komada M. Research and Development Activities on Negative Ion Sources. FUSION SCIENCE AND TECHNOLOGY 2017. [DOI: 10.13182/fst10-a10835] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
109
|
Yamamoto M, Shibata T, Tsuzuki K, Sato M, Kimura H, Okano F, Kawashima H, Suzuki S, Shinohara K, Urata K. Engineering Design, Installation, and Conditioning of Ferritic Steel Plates/Wall for AMTEX in JFT-2M. FUSION SCIENCE AND TECHNOLOGY 2017. [DOI: 10.13182/fst06-a1098] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
110
|
Tsuzuki K, Kimura H, Kusama Y, Sato M, Kawashima H, Kamiya K, Shinohara K, Ogawa H, Uehara K, Kurita G, Kasai S, Hoshino K, Isei N, Miura Y, Yamamoto M, Kikuchi K, Shibata T, Bakhtiari M, Hino T, Hirohata Y, Yamauchi Y, Yamaguchi K, Tsutsui H, Shimada R, Amemiya H, Nagashima Y, Ido T, Hamada Y. Characteristics of Plasma Operation with the Ferritic inside Wall and Its Compatibility with High-Performance Plasmas in JFT-2M. FUSION SCIENCE AND TECHNOLOGY 2017. [DOI: 10.13182/fst06-a1095] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
111
|
Shimozuma T, Takahashi H, Kubo S, Yoshimura Y, Igami H, Takita Y, Kobayashi S, Ito S, Mizuno Y, Idei H, Notake T, Sato M, Ohkubo K, Watari T, Mutoh T, Minami R, Kariya T, Imai T. ECRH-Related Technologies for High-Power and Steady-State Operation in LHD. FUSION SCIENCE AND TECHNOLOGY 2017. [DOI: 10.13182/fst58-530] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
112
|
Shinohara K, Sato M, Kawashima H, Tsuzuki K, Suzuki S, Urata K, Isei N, Tani T, Kikuchi K, Shibata T, Kimura H, Miura Y, Kusama Y, Yamamoto M. Ripple Reduction with Ferritic Insert in JFT-2M. FUSION SCIENCE AND TECHNOLOGY 2017. [DOI: 10.13182/fst06-a1094] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
113
|
Nakano M, Oinuma M, Sato M, Asari J, Watanabe K, Kikuchi Y, Sakuma H. P12.18 A case of malignant meningioma with long-term recurrence free survival. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox036.375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
114
|
Takahashi M, Nishiyama Y, Hara F, Naito Y, Baba M, Sasaki M, Sato M, Watanabe K, Uemura Y, Yamaguchi T, Mukai H. Abstract P4-21-03: A randomized phase II study of Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-21-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
As for the HER2-positive breast cancer, there are many cases to be effective for neoadjuvant chemotherapy in comparison with other intrinsic subtypes. However, pCR is not provided by neoadjuvant chemotherapy in all cases. [Aim] This study evaluated the effectiveness of a therapeutic strategy that switches chemotherapy, based on Ki-67 tumor expression after initial therapy, relative to that of standard chemotherapy in patients with HER2-positive breast cancer. [patients and methods] Patients were randomly assigned to the control arm or the Ki-67 response-guided arm (Ki-67 arm). Primary tumor biopsies were obtained before treatment, and after three once-weekly doses of paclitaxel and trastuzumab to assess the interim Ki-67 index. In the control arm, paclitaxel and trastuzumab was continued for a total of 12 doses, regardless of the interim Ki-67 index. In the Ki-67 arm, subsequent treatment was based on the interim Ki-67 index. Early Ki-67 responders continued to received paclitaxel plus trastuzumab for a total of 12 doses, while early Ki-67 non-responders were switched to epirubicin plus cyclophosphamide every 3 weeks for three cycles with once-weekly trastuzumab for a total of 12 doses. The primary endpoint was the pathological complete response (pCR) rate. [Results] When 237 patients were enrolled, an interim analysis was conducted in 200 patients. There was almost linear correlation between the Ki-67 reduction rate at interim assessment and the pCR rate. The pCR rate in Ki-67 early non-responders in the Ki-67 arm (23.6%; 95% CI, 12.4 to 34.9) was inferior to that in the control arm (44.1%; 31.4 to 56.7; p=0.025). A strong correlation was not found between the Ki-67 reduction rate and the clinical response rate (Spearman's correlation coefficient 0.22).
pCR rate among Ki-67 early non-responders and responders TotalpCR nn%95%CIKi-67 early non responderControl arm59264431.4-56.7 Ki-67 response guided arm55132312.4-34.9Ki-67 early responderControl arm21104726.3-69.0 Ki-67 response guided arm2084018.5-61.5
Conclusions: The pCR rate in the Ki-67 arm was inferior to that in the control arm. A therapeutic strategy that switches chemotherapy, based on Ki-67 tumor expression after initial therapy, was not effective. The standard chemotherapy protocol remains as the recommended strategy for patients with HER2-positive breast cancer.
Citation Format: Takahashi M, Nishiyama Y, Hara F, Naito Y, Baba M, Sasaki M, Sato M, Watanabe K, Uemura Y, Yamaguchi T, Mukai H. A randomized phase II study of Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-21-03.
Collapse
|
115
|
Abe S, Yoshimoto T, Yamamoto M, Sato M, Yanagisawa N, Hinata N, Abe H, Gen M. Midline sensory nerve supply to the anoscrotal junction: a study using human male fetuses. Okajimas Folia Anat Jpn 2017; 94:17-25. [PMID: 29213015 DOI: 10.2535/ofaj.94.17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
The origin of the posterior scrotal nerve is considered to be the bilateral pudendal nerves but the course to the midline is still obscure. Using 5 late-stage human male fetuses, we identified the single nerve through the intramuscular midline septum of the bulbospongiosus and the bilateral nerves along the left and right sides of the septum. Thus, the posterior scrotal nerve showed a variation: a single midline trunk or bilateral nerves. Branches of the bilateral pudendal nerves ran medially between the muscle and Cowper's gland and, at the midline area, they joined or associated closely. During the proximal course, much or less, the nerve penetrated the superior part of the muscle. The nerve entered the subcutaneous tissue at and near the perineal raphe. The communication with intrapelvic autonomic nerves were suggested behind Cowper's gland. Notably, the midline skin immediately anterior to the anus carried a considerable dense supply of thin sensory nerves. However, these nerves seemed to come from a space between the rectal smooth muscle and the external anal sphincter, not from the posterior scrotal nerve. Therefore, surgical treatment of the intersphincteric layer was likely to injure the original sensory nerve supply to the anterior anal skin.
Collapse
|
116
|
Nakagawa H, Kim SW, Hasegawa T, Hasegawa S, Ishigaki T, Uematsu K, Toda K, Takaba H, Sato M. Stabilization of novel high temperature phase yellow-emitting σ-type (Ba1−x−yEuxMgy)2P2O7 phosphors using a melt synthesis technique. Inorg Chem Front 2017. [DOI: 10.1039/c7qi00359e] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Novel high-temperature phase σ-type (Ba1−x−yEuxMgy)2P2O7 phosphors were synthesized for the first time by a melt synthesis technique using an arc-imaging furnace.
Collapse
|
117
|
Kim SW, Hasegawa T, Muto M, Toda A, Kaneko T, Sugimoto K, Uematsu K, Ishigaki T, Toda K, Sato M, Koide J, Toda M, Kudo Y. Improvement of luminescence properties of rubidium vanadate, RbVO3, phosphors by erbium doping in the crystal lattice. NEW J CHEM 2017. [DOI: 10.1039/c6nj03823a] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The thermal quenching effect of RbVO3 phosphor was effectively improved by Er3+ doping into the lattice, as a result, the emission intensity of the phosphor was successfully enhanced.
Collapse
|
118
|
Sato M, Takeda T, Hoshino N, Akutagawa T. Electronic and crystal structures of 1,2,3-triazole-fused p-benzoquinone derivatives. CrystEngComm 2017. [DOI: 10.1039/c6ce02167k] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
119
|
Abe S, Tomita N, Yamamoto M, Sato M, Abe H, Murakami G, Rodríguez-Vázquez JF. Topographical anatomy of the pronator teres muscle and median nerve: a study using histological sections of human fetuses. Okajimas Folia Anat Jpn 2017; 94:37-44. [PMID: 29213017 DOI: 10.2535/ofaj.94.37] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
The median nerve passes through the humeral and ulnar heads of the pronator teres muscle (PT), although variations such as absence of the ulnar head may exist. We observed histological sections of the upper extremity from 24 embryos and fetuses. In the early stage, the PT extended between the radius and the medial epicondyle of the humerus, but no candidate for the ulnar head was found. In mid-term fetuses, the ulnar margin of the PT was attached to the elbow joint capsule. Moreover, in late-stage fetuses, a small deep part of the PT arose from the thick joint capsule of the humero-ulnar joint near the coronoid process of the ulna. This joint capsule also provided the most proximal origin of the flexor digitorum profundus muscle. Therefore, we considered fetal PT origin from the capsule as a likely candidate for the ulnar head. Consequently, the PT seemed to develop from a single anlage through which the median nerve passed, but later - possibly after birth - a small PT origin from the joint capsule appeared to obtain an aponeurosis connecting the muscle fiber to the ulna. This secondary change in PT morphology might explain the muscle variation seen in adults.
Collapse
|
120
|
Mochizuki H, Fujiwara-Igarashi A, Sato M, Goto-Koshino Y, Ohno K, Tsujimoto H. Genetic and epigenetic aberrations of p16 in feline primary neoplastic diseases and tumor cell lines of lymphoid and non-lymphoid origins. Vet J 2016; 219:27-33. [PMID: 28093106 DOI: 10.1016/j.tvjl.2016.11.017] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2016] [Revised: 11/15/2016] [Accepted: 11/29/2016] [Indexed: 12/25/2022]
Abstract
The p16 gene acts as a tumor suppressor by regulating the cell cycle and is frequently inactivated in human and canine cancers. The aim of this study was to characterize genetic and epigenetic alterations of the p16 in feline lymphoid and non-lymphoid malignancies, using 74 primary tumors and 11 tumor cell lines. Cloning of feline p16 and subsequent sequence analysis revealed 11 germline sequence polymorphisms in control cats. Bisulfite sequencing analysis of the p16 promoter region in a feline lymphoma cell line revealed that promoter methylation was associated with decreased mRNA expression. Treatment with a demethylating agent restored mRNA expression of the silenced p16. PCR amplification and sequencing analysis detected homozygous loss (five tumors, 6.7%) and a missense mutation (one tumor, 1.4%) in the 74 primary tumors analyzed. Methylation-specific PCR analysis revealed promoter methylation in 10 primary tumors (14%). Promoter methylation was frequent in B cell lymphoid tumors (7/21 tumors, 33%). These genetic and epigenetic alterations were also observed in lymphoma and mammary gland carcinoma cell lines, but not detected in non-neoplastic control specimens. These data indicate that molecular alterations of the p16 locus may be involved in the development of specific types of feline cancer, and warrant further studies to evaluate the clinical value of this evolutionarily-conserved molecular alteration in feline cancers.
Collapse
|
121
|
Uchida T, Kishimoto T, Koreki A, Nakao S, Owada A, Koizumi T, Saito A, Sato M, Sawada S, Matsuzaki R, Petrides G, Mimura M. Predictors of readmission after successful electroconvulsive therapy for depression: a chart review study. Int J Psychiatry Clin Pract 2016; 20:260-4. [PMID: 27541857 DOI: 10.1080/13651501.2016.1209220] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
OBJECTIVE The study aimed to identify the predictors for readmission after a successful electroconvulsive therapy (ECT) course. METHODS Medical charts of patients who received ECT for major depressive episodes were reviewed. Patients' demographic characteristics and treatment parameters, such as ECT charge, seizure duration, the number of ECT sessions and pharmacotherapy, were extracted. We compared differences between those who were readmitted after successful ECT within 6 and 12 months, versus those not readmitted. We also conducted a multivariate logistic regression analysis to identify the predictors for readmission. RESULTS Out of 51 patients who were discharged after ECT, 27 patients met the inclusion criteria and were included in the analysis. Eight patients were readmitted within 6 months after discharge, and four more patients were readmitted during the next 6-month follow up. Comparing patients who were and were not readmitted, we found no significant differences between groups, including ECT parameters such as the number of ECT sessions, average charge and final charge. No predictors for readmission were found through multivariate analysis. CONCLUSIONS Although patients who require higher ECT charge and more sessions seem to be prone to readmission, our dataset suggested that none of these types of ECT parameters were risk factors for readmission.
Collapse
|
122
|
Hirose K, Aoki M, Sato M, Akimoto H, Hatayama Y, Kawaguchi H, Hashimoto Y, Imai A, Kamimura N, Fujioka I, Tanaka M, Ohyama C, Takai Y. A Retrospective Analysis of the Relationship Between Prescribed Dose and Dosimetric Advantage Taken by Intraoperative Built Custom Linked Seeds in Iodine-125 Prostate Brachytherapy. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.1261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
123
|
Hatayama Y, Aoki M, Kawaguchi H, Hirose K, Sato M, Akimoto H, Takai Y. Preliminary Results of Accelerated Hypofractionated Radiation Therapy for Small Central Lung Tumors. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.1790] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
124
|
Aoki M, Akimoto H, Sato M, Hirose K, Kawaguchi H, Hatayama Y, Fujioka I, Tanaka M, Ono S, Takai Y. Impact of Pretreatment Whole-Tumor Perfusion Computed Tomography and 18f-Fluorodeoxyglucose Positron Emission Tomography Measurements on Local Control of Lung Tumor Treated With Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.1745] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
125
|
Suzuki T, Miyake N, Tsurusaki Y, Okamoto N, Alkindy A, Inaba A, Sato M, Ito S, Muramatsu K, Kimura S, Ieda D, Saitoh S, Hiyane M, Suzumura H, Yagyu K, Shiraishi H, Nakajima M, Fueki N, Habata Y, Ueda Y, Komatsu Y, Yan K, Shimoda K, Shitara Y, Mizuno S, Ichinomiya K, Sameshima K, Tsuyusaki Y, Kurosawa K, Sakai Y, Haginoya K, Kobayashi Y, Yoshizawa C, Hisano M, Nakashima M, Saitsu H, Takeda S, Matsumoto N. Molecular genetic analysis of 30 families with Joubert syndrome. Clin Genet 2016; 90:526-535. [PMID: 27434533 DOI: 10.1111/cge.12836] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2016] [Revised: 06/27/2016] [Accepted: 07/14/2016] [Indexed: 02/02/2023]
Abstract
Joubert syndrome (JS) is rare recessive disorders characterized by the combination of hypoplasia/aplasia of the cerebellar vermis, thickened and elongated superior cerebellar peduncles, and a deep interpeduncular fossa which is defined by neuroimaging and is termed the 'molar tooth sign'. JS is genetically highly heterogeneous, with at least 29 disease genes being involved. To further understand the genetic causes of JS, we performed whole-exome sequencing in 24 newly recruited JS families. Together with six previously reported families, we identified causative mutations in 25 out of 30 (24 + 6) families (83.3%). We identified eight mutated genes in 27 (21 + 6) Japanese families, TMEM67 (7/27, 25.9%) and CEP290 (6/27, 22.2%) were the most commonly mutated. Interestingly, 9 of 12 CEP290 disease alleles were c.6012-12T>A (75.0%), an allele that has not been reported in non-Japanese populations. Therefore c.6012-12T>A is a common allele in the Japanese population. Importantly, one Japanese and one Omani families carried compound biallelic mutations in two distinct genes (TMEM67/RPGRIP1L and TMEM138/BBS1, respectively). BBS1 is the causative gene in Bardet-Biedl syndrome. These concomitant mutations led to severe and/or complex clinical features in the patients, suggesting combined effects of different mutant genes.
Collapse
|